Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors

Viruses

Volumn 3, Issue 5, 2011, Pages 469-483

  Macchi, Beatrice ^a,e   Balestrieri, Emanuela ^a   Ascolani, Arianna ^a   Hilburn, Silva ^b   Martin, Fabiola ^c   Mastino, Antonio ^d,f   Taylor, Graham P ^b,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d UNIVERSITY OF MESSINA   (Italy)

^e IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^f IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Azidothymidine; Drug sensitivity; Human t cell lymphotropic virus type 1; Lamivudine; Phosphonated carbocyclic 2' oxa 3'aza nucleosides; Primary isolates; Reverse transcriptase; Tenofovir

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; INTEGRASE; LAMIVUDINE; PHOSPHONATED CARBOCYCLIC 2' OXA 3' AZA NUCLEOSIDE; PHOSPHONATED CARBOCYCLIC 2' OXA 3' AZA NUCLEOSIDE 1; PHOSPHONATED CARBOCYCLIC 2' OXA 3' AZA NUCLEOSIDE 2; PHOSPHONATED CARBOCYCLIC 2' OXA 3' AZA NUCLEOSIDE 3; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINE; CODON; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTYPE; HTLV 1 ASSOCIATED MYELOPATHY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; SEXUAL DYSFUNCTION; SPASTIC PARAPLEGIA; TREATMENT DURATION; URINARY DYSFUNCTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS RELEASE; VIRUS TRANSMISSION;

ADULT; CELL LINE; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; YOUNG ADULT;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 79957825247     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v3050469     Document Type: Article

References (25)

1. Gessain, A.; Vernant, J.C.; Maurs, L.; Barin, F.; Gout, O.; Calender, A.; de Thé, G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, ii, 407-409.
2. Kaplan, J.E.; Osame, M.; Kubota, H.; Igata, A.; Nishitani, H.; Maeda, Y., Khabbaz, R.F.; Janssen, R.S. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J. Acquir. Immune. Defic. Syndr. 1990, 3, 1096-1101.
3. Maloney, E.M.; Cleghorn, F.R.; Morgan, O.S.; Rodgers-Johnson, P.; Cranston, B.; Jack, N.; Blattner, W.A.; Bartholomew, C.; Manns, A. Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J. Acquir. Immune. Defic. Syndr. Hum Retrovirol 1998, 17, 167-170.
4. Nagai, M.; Usuku, K.; Matsumoto, W.; Kodama, D.; Takenouchi, N.; Moritoyo, T.; Hashiguchi, S.; Ichinose, M.; Bangham, C.R.; Izumo, S.; Osame, M. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: High proviral load strongly predisposes to HAM/TSP. J. Neurovirol. 1998, 4, 586-593.
5. Taylor, G.P.; Tosswill, J.H.C.; Matutes, E.; Daenke, S.; Hall, S.; Bain, B.J.; Davis, R.; Thomas, D.; Rossor, M.; Bangham, C.R.; Weber, J.N. Prospective Study of HTLV-I infection in an initially asymptomatic UK cohort. J. Acquir. Immune. Defic. Syndr. 1999, 22, 92-100.
6. Macchi, B.; Faraoni, I.; Zhang, J.; Grelli, S.; Favalli, C.; Mastino, A.; Bonmassar, E. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J. Gen. Virol. 1997, 78, 1007-1016.
7. Balestrieri, E.; Forte, G.; Matteucci, C.; Mastino, A.; Macchi, B. Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrob. Agents Chemother. 2002, 46, 3080-3083.
8. Garcia-Lerma, J.G.; Nidtha, S.; Heneine, W. Susceptibility of Human T Cell Leukaemia Virus Type 1 to Reverse-transcriptase inhibitors: evidence of resistance to lamivudine. J. Infect. Dis. 2001, 184, 507-510.
9. Toro, C.; Rodés, B.; Mendoza, C.d. C.; Soriano, V. Lamivudine resistance in human T-cell leukaemia virus type 1 may be due to a polymorphism at codon 118 (V → I) of the reverse transcriptase. Antimicrob. Agents Chemother. 2003, 47, 1774-1775.
10. Chiacchio, U.; Balestrieri, E.; Macchi, B.; Iannazzo, D.; Piperno, A.; Rescifina, A.; Romeo, R.; Saglimbeni, M.; Sciortino, M.T.; Valveri, V, et al. Synthesis of Phosphonated Carbocyclic 2'-Oxa-3'-aza-nucleosides: Novel Inhibitors of Reverse Transcriptase. J. Med. Chem. 2005, 48, 1389-1394.
11. Macchi, B. Triphosphorylated AZT inhibited HTLV-1 RT in vitro at much lower concentrations than triphosphorylated 3TC. Department of Neuroscience, University of Rome, Rome, Italy. Unpublished data, 2008.
12. Balestrieri, E.; Sciortino, M.T.; Mastino, A.; Macchi, B. Protective effect of the acyclic nucleoside phosphonate tenofovir toward human T-cell leukemia/lymphotropic virus type 1 infection of human peripheral blood mononuclear cells in vitro. Antivir. Res. 2005, 68, 154-162.
13. Balestrieri, E.; Matteucci, C.; Ascolani, A.; Piperno, A.; Romeo, R.; Romeo, G.; Chiacchio, U.; Mastino, A.; Macchi, B. Effect of Phosphonated Carbocyclic 2'-Oxa-3'-Aza-Nucleoside on Human T-Cell Leukemia Virus Type 1 Infection in vitro. Antimicrob. Agents Chemother. 2008, 52, 54-64.
14. Isono, T.; Ogawa, K.; Seto, A. Antiviral effect of zidovudine in the experimental model of adult T-cell leukaemia in rabbits. Leuk. Res. 1990, 14, 841-847.
15. Taylor, G.P.; Hall, S.E.; Navarette, S.; Michie, C.A.; Davis, R.; Witkover, A.D.; Rossor, M.; Nowak, M.A.; Rudge, P.; Matutes, E.; Bangham, C.R.; Weber, J.N. Effect of Lamivudine on human T-cell leukaemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-Tax cytotoxic T-cell frequency in patients with HTLV-1 associated myelopathy. J. Virol. 1999, 73, 10289-10295.
16. Taylor, G.P.; Goon, P.; Furukawa, Y.; Green, H.; Barfield, A.; Mosley, A.; Nose, H.; Babiker, A.; Rudge, P.; Usuku, K; et al. Zidovudine plus lamivudine in Human T-lymphotropic virus type Iassociated myelopathy: A randomised trial. Retrovirology 2006, 3, 63.
17. Hill, S.A.; Lloyd, P.A.; McDonald, S.; Wykoff, J.; Derse, D. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. J. Infect. Dis. 2003, 188, 424-427.
18. Goon, P.; Igakura, T.; Hanon, E.; Mosley, A.J.; Barfield, A.; Barnard, A.; Kaftantzi, L.; Tanaka, Y.; Taylor, G.P.; Weber, J.N.; Bangham, C.R.M. HTLV-I specific CD4+ T cells: Immunodominance hierarchy and preferential infection with HTLV-I. J. Immunol. 2004, 172, 1735-1743.
19. Chiacchio, U.; Corsaro, A.; Iannazzo, D.; Piperno, A.; Pistara, V.; Rescifina, A.; Romeo, R.; Valveri, V.; Mastino, A.; Romeo, G. Enantioselective Syntheses and Cytotoxicity of N,O-Nucleosides. J. Med. Chem. 2003, 46, 3696-3702.
20. Chiacchio, U.; Rescifina, A.; Iannazzo, D.; Piperno, A.; Romeo, R.; Borrello, L.; Sciortino, MT.; Balestrieri, E.; Macchi, B.; Mastino, A.; Romeo, G. Phosphonated Carbocyclic 2'-Oxa-3'- aza-nucleosides as new antiretroviral agents. J. Med. Chem. 2007, 50, 3747-3750.
21. Medici, M.A.; Sciortino, M.T.; Perri, C.; Amici, E.; Avitabile, E.; Ciotti, M.; Balestrieri, E.; De Smaele, E.; Franzoso, G.; Mastino, A. Protection by herpes simplex virus glycoprotein D against Fas-medianted apoptosis: Role of nuclear factor kappa B. J. Biol. Chem. 2003, 278, 36059-36067.
22. Morozov, V.A.; Lagaye, S.; Taylor, G.P.; Matutes, E.; Weiss, R.A. Chimeric matrix proteins encoded by defective proviruses with large internal deletions in Human T-cell Leukemia Virus Type-I infected humans. J. Virol. 2000, 74, 3933-3940.
23. Gillet, N.; Malani, N.; Gormley, N.; Carter, R.; Melamed, A.; Bentley, D.; Berry, C.; Bushman, C.R.; Taylor, G.P.; Bangham, C.R.M. The host genomic environment of the provirus determines the abundance of HTLV-1 infected T-cell clones. Blood 2011, 117, 3113-3122.
24. Afonso, P.V.; Mekaouche, M.; Mortreux, F.; Toulza, F.; Moriceau, A.; Wattel, E.; Gessain, A.; Bangham, C.R.M.; Dubreuil, G.; Plumelle, Y;et al. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood 2010, 116, 3802-3808.
25. Tan, C.; Waldmann, T.A. Proteasome Inhibitor PS-341, a Potential Therapeutic Agent for Adult T-Cell Leukemia. Cancer Res. 2002, 62, 1083-1086.